NovaBay Pharmaceuticals Now Included in EPA N Listing of Products That Kill SARS-CoV-2

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces its proprietary hypochlorous acid solution has received U.S. Environmental Protection Agency (EPA) approval for a kill claim against SARS-CoV-2, the virus that causes COVID-19. This official listing follows the July 2020 announcement that independent, third-party laboratory results demonstrated that NovaBay’s proprietary formulation kills SARS-CoV-2 on hard surfaces.

“The FDA requires that any product containing hypochlorous acid (HOCl) used by patients in healthcare is registered as a medical device and may be marketed as either a prescription (Rx) or over-the-counter (OTC) product following its intended use label guidelines. However, it is the EPA that regulates disinfectants on surfaces and requires formal testing of such products to make any disinfectant claims, even if the ingredients are the same as the FDA-registered product,” said Justin Hall, NovaBay’s CEO. “Obtaining EPA Registration Number 98003-1 for NovaBay Hard Nonporous Surface Pro is a validation that our HOCl solution is effective against the virus and can be used by consumers to safely disinfect commonly used personal items like eyeglasses, facial coverings, and cell phones.”

Hypochlorous acid has been used for more than 100 years by medical professionals for disinfecting medical equipment and dressing wounds. Until recently, all HOCl solutions contained toxic chemicals like sodium hypochlorite, or were very unstable and could not be stored for long periods of time. In 2015, NovaBay revolutionized the HOCl marketplace with a pure and stable formulation, devoid of bleach particles and toxic impurities.

“The special characteristics of NovaBay’s proprietary HOCl, plus state-of-the-art manufacturing in the USA, set it apart from all other hypochlorous acid products,” added Mr. Hall. “We are highly pleased that our years of research and development, independent laboratory testing, and our interaction with the EPA have culminated in NovaBay Hard Nonporous Surface Pro’s recognition for use in combating the spread of the coronavirus.”

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, CELLERX® for the aesthetic dermatology market and NEUTROPHASE® for the wound care market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the regulatory clearance of any of our products or future products, and any future revenue that may result from selling these products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay informed on NovaBays progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBays Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com

Contacts:

NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.